These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8485045)

  • 81. Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-alpha (rIFN alpha 2a) and neutralizing-rIFN alpha 2a antibodies negative.
    Russo D; Candoni A; Grattoni R; Minisini R; Rosti G
    Haematologica; 1997; 82(3):348-50. PubMed ID: 9234589
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia.
    Bonifazi F; De Vivo A; Rosti G; Tiribelli M; Russo D; Trabacchi E; Fiacchini M; Montefusco E; Baccarani M
    Br J Haematol; 2000 Nov; 111(2):587-95. PubMed ID: 11122107
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Hematologic and cytogenetic response to treatment in patients with chronic myeloid leukemia].
    Tóthová E; Fricová M; Stecová N; Kafková A; Mudronová B; Svorcová E; Guman T; Raffac S; Hlebasková M
    Cas Lek Cesk; 2000 Jul; 139(14):437-9. PubMed ID: 11048406
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
    Sacchi S; Kantarjian HM; Freireich EJ; O'Brien S; Cortes J; Rios MB; Kornblau S; Giles FJ; Koller C; Gajewski J; Talpaz M
    Leuk Lymphoma; 1999 Nov; 35(5-6):483-9. PubMed ID: 10609785
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Chronic myeloid leukemia in first chronic phase not responding to alpha-interferon: outcome and prognostic factors after autologous transplantation. EBMT Working Party on Chronic Leukemias.
    Boiron JM; Cahn JY; Meloni G; Carlo-Stella C; Bandini G; Reman O; Milpied N; Apperley J; Reiffers J
    Bone Marrow Transplant; 1999 Aug; 24(3):259-64. PubMed ID: 10455363
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Interferon alpha-2b as therapy for patients with Ph'-positive chronic myelogenous leukemia.
    Alimena G; Morra E; Lazzarino M; Liberati AM; Montefusco E; Inverardi D; Bernasconi P; Mancini M; Donti E; Grignani F
    Eur J Haematol Suppl; 1990; 52():25-8. PubMed ID: 2279541
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Discordant neutrophil alkaline phosphatase activity and cytogenetic response in chronic myeloid leukemia treated with alpha-interferon.
    Taylor DL; Kerwick AM; Elliott SL; Rodwell RL; Wright SJ; Marlton PV; Veleba AR; Taylor KM
    Pathology; 1993 Oct; 25(4):363-6. PubMed ID: 8165000
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Cytogenetic remission 10 years after the start of monotherapy with interferon alpha-2b in elderly chronic myelogenous leukemia].
    Umeda M; Katoh M; Arai C; Iijima K
    Nihon Ronen Igakkai Zasshi; 2003 Sep; 40(5):520-5. PubMed ID: 14579725
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Prognostic impact of bone marrow erythropoietic precursor cells and myelofibrosis at diagnosis of Ph1+ chronic myelogenous leukaemia--a multicentre study on 495 patients.
    Kvasnicka HM; Thiele J; Schmitt-Graeff A; Diehl V; Zankovich R; Niederle N; Leder LD; Schaefer HE
    Br J Haematol; 2001 Mar; 112(3):727-39. PubMed ID: 11260078
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Interferon therapy for Ph1-positive chronic myelogenous leukaemia patients relapsing after T-cell depleted allogeneic bone marrow transplantation.
    Arcese W; Mauro FR; Screnci M; Alimena G; Lo Coco F; Iori AP; de Cuia MR; Fazi P; Montefusco E; Mandelli F
    Eur J Cancer; 1991; 27 Suppl 4():S28-30. PubMed ID: 1799471
    [No Abstract]   [Full Text] [Related]  

  • 92. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha.
    Russo D; Candoni A; Zuffa E; Minisini R; Silvestri F; Fanin R; Zaja F; Martinelli G; Tura S; Botta G; Baccarani M
    Br J Haematol; 1996 Aug; 94(2):300-5. PubMed ID: 8759890
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Continuous oral cytarabine ocfosfate with interferon-alpha-2b for patients with newly diagnosed chronic myeloid leukaemia: a pilot study.
    del Cañizo MC; Fisac MP; Galende J; Hurtado JA; Moro MJ; Rodriguez JA; Rivas JM; Tabernero MD;
    Br J Haematol; 2001 Dec; 115(3):541-4. PubMed ID: 11736933
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Hydroxyurea versus interferon alfa-2b in chronic myelogenous leukaemia: preliminary results of an open French multicentre randomized study.
    Broustet A; Reiffers J; Marit G; Fiere D; Jaubert J; Reynaud J; Pris J; Bernard P; Charrin C; Wen ZQ
    Eur J Cancer; 1991; 27 Suppl 4():S18-21. PubMed ID: 1799467
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Cutaneous sarcoidosis in a patient with Philadelphia-positive chronic myelogenous leukemia treated with interferon-alpha.
    Yavorkovsky LL; Carrum G; Bruce S; McCarthy PL
    Am J Hematol; 1998 May; 58(1):80-1. PubMed ID: 9590155
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A possible correlation between interferon-stimulated gene expression and cytogenetic responses in chronic myelogenous leukemia patients treated with alpha-interferon.
    Kawakubo K; Ohyashiki K; Ohyashiki JH; Shimamoto T; Fujimura T; Iwama H; Toyama K
    Jpn J Clin Oncol; 1996 Apr; 26(2):59-64. PubMed ID: 8609695
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Unmaintained cytogenetic and molecular remission in chronic myelogenous leukaemia following treatment by interferon.
    Rio B; Ramond S; Lacorte JM; Pépin D; Barbu V; Viguie F; Ajchenbaum-Cymbalista F; Lorrot M; Chambaz J; Zittoun R
    Br J Haematol; 1996 Feb; 92(2):504-5. PubMed ID: 8603027
    [No Abstract]   [Full Text] [Related]  

  • 98. Identification of a complex formed between nuclear proteins and the transcriptional enhancer of interferon-inducible genes that is present in the peripheral blood myeloid cells of CML but not normal individuals.
    Seong DC; Gottlieb K; Suh SP; Sims S; Talpaz M; Kantarjian H; Deisseroth A
    J Interferon Res; 1992 Oct; 12(5):323-7. PubMed ID: 1431311
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Natural history and staging of chronic myelogenous leukaemia.
    Cortes J; Kantarjian HM; Giralt S; Talpaz M
    Baillieres Clin Haematol; 1997 Jun; 10(2):277-90. PubMed ID: 9376664
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon α.
    Kreil S; Waghorn K; Ernst T; Chase A; White H; Hehlmann R; Reiter A; Hochhaus A; Cross NC;
    Haematologica; 2010 Jan; 95(1):148-52. PubMed ID: 20065083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.